Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Proteros biostructures GmbH announced they entered into a Lead Discovery Collaboration with Priaxon AG to jointly develop lead compounds for high value protein-protein interaction (PPI) drug targets.

The combination of Proteros’ structure guided discovery with Priaxon’s PPI-directed drug discovery platforms will be focused on the identification of novel small molecule modulators for PPI targets. As part of this collaboration, Proteros will apply its integrated Lead Discovery expertise and technologies in the field of structural biology, biophysics and screening. Priaxon will apply its proprietary drug discovery platform  Priaxplore®, which combines a proprietary PPI focused chemical space with special tailor made chemoinformatic methods for the identification of potential PPI modulators.

“The combination of Proteros’ strength in structural biology and biophysics with the Priaxon’s PPI focused drug discovery platform Priaxplore® forms an excellent basis to make PPI targets of high interest addressable by small molecule modulators" said Dr. Juergen Kolb, CEO of Priaxon.

Dr. Torsten Neuefeind, CEO of Proteros, stated: "We are very pleased to have formed this relationship with Priaxon. Both companies have complementary platforms as well as an established track-record. PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons’ validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteros, Merck Sharp & Dohme Corp. Collaborate
Proteros to receive upfront and research funding plus milestone payments of up to $126 million plus royalties.
Wednesday, October 07, 2015
Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer
Dr. Hoffmann will support the further growth of the Company’s Discovery business.
Tuesday, June 30, 2015
Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
Company to discover potent and selective small molecule inhibitor series against a novel protein target.
Tuesday, May 19, 2015
Proteros Enters into a Collaboration with Bayer
Collaboration to develop new cardiovascular drug compounds for an integral membrane protein.
Saturday, January 10, 2015
Proteros Announces Changes in Management Team
The changes see a new Chief Financial Officer, and a promotion to Chief Operating Officer.
Monday, May 12, 2014
Proteros Elects New Supervisory Board Member
Shareholders confirmed the appointment of Prof. Eric-Paul Pâques as a new member of the Supervisory Board.
Thursday, February 20, 2014
Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders
Founded by Atlas Venture and Proteros biostructures.
Monday, July 01, 2013
Proteros and Eisai Announces Successful Completion of Collaboration
Proteros and Eisai achieve target in lead discovery project, delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
Proteros and Eisai Achieve Target in Lead Discovery Project
Companies delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
UCB and Proteros Expand Collaboration
Expansion of the ongoing structural biology collaboration will include additional therapeutic areas.
Monday, September 17, 2012
Proteros Announces Successful Close of Financing Round
Largest-ever financing allows for expansion of drug discovery capabilities.
Tuesday, August 07, 2012
Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
Companies partner to identify small molecule inhibitors.
Monday, April 16, 2012
Proteros Appoints Dr Klaus Hinterding
Dr Klaus Hinterding, formerly at Hoffmann-La Roche Ltd, joins Proteros biostructures GmbH as Chief Scientific Officer and member of the management board.
Monday, February 13, 2012
Proteros Obtains CIR Accreditation
Accreditation allows eligible clients to receive 30% of their R&D costs in tax credits.
Wednesday, January 25, 2012
Rigel and Proteros Renew X-ray Protein Crystallography Collaboration
Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Thursday, August 04, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos